Recent Updates
Recently added Catalysts
KNSA Positive Sentiment

Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026

Key Takeaway: Kiniksa Pharmaceuticals will host a conference call on October 27, 2026, to discuss its third quarter financial results and recent portfolio developments. The event will be accessible via webcast and telephone registration. A replay will be available on the company's website shortly after the call.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kiniksa will report third quarter 2026 financial results.
  • The company focuses on improving patient lives.
  • Kiniksa's portfolio targets unmet medical needs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+62%
120-day peak, hindsight
Typical move
3.7%
average across 2 past catalysts
Lead asset
KPL-404
Phase 2 · Arthritis, Rheumatoid

Full Press Release Details

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ®

Kiniksa Investor & Media Contact Jonathan Kirshenbaum (781) 829-3949 jkirshenbaum@kiniksa.com

Frequently Asked Questions

When will Kiniksa report its Q3 2026 results?

Kiniksa will report its Q3 2026 results on October 27, 2026.

How can I access the Kiniksa conference call?

The conference call can be accessed via webcast or telephone registration.

Is there a replay available for the Kiniksa call?

Yes, a replay will be available on Kiniksa's website within 48 hours.

What is Kiniksa's focus in biopharmaceuticals?

Kiniksa focuses on therapies for debilitating diseases, especially cardiovascular indications.

Last updated: Oct 22, 2026